A variety of markers combined use of clinical significance for diagnosis of prostate cancer
A variety of markers combined use of clinical significance for diagnosis of prostate cancer作者机构：The First Affiliated Hospital of Jiamusi UniversityJiamusi154003HeilongjiangChina
出 版 物：《Journal of Hainan Medical University》 (海南医学院学报（英文版）)
年 卷 期：2018年第24卷第20期
页 面：69-71页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：1. Heilongjiang Natural Science Fund. 2. Key Project of Science and Technology of Jiamusi University. Project No: 1. D201225 2. 12Z1201504
主 题：Prostate cancer (PCa) A formyl Kiev enzyme a racemase (AMACR) P63 CK34βE12
摘 要：Objective:To explore the combined application of multiple markers for diagnosis of prostate ***:To choose the hospital in September, 2015 to September 2012, initially determined both by serum PSA test for prostate cancer patients 117 cases, for patients with confirmed will be divided into three groups (39 cases further examination, compared with the pathological diagnosis of three groups of patients with prostate cancer diagnosis accuracy. Results: The detection rate in group A patients compared with the pathological diagnosis coincidence rate was 77.2%, B group was 90.3%, and 98.2% of group C, A, B two groups were lower in group C, group A and group B was higher than that that P504s inspection diagnosis rate is higher than about, CK34 beta E12 at 11:45, joint detection and diagnosis rate is highest. Three groups of patients were compared with difference had statistical significance . A group of 13 cases of benign specimen, 10 cases were negative, false positive in 3, coincidence rate was 76.9%, B group of 12 cases of benign specimens, the negative in 11 cases, false positives in 1 case, the coincidence rate is 91.7%, group C of 11 cases of benign specimens, negative in 11 cases, false positive 0 cases, coincidence rate was 100%. Combined detection of false positive diagnosis rate was lower than that in group A, B two patients, three groups of patients were compared with difference had statistical significance. Group A in 26 cases of prostate cancer, positive 22 cases, 4 cases were missed diagnosis coincidence rate was 84.6%. Group B in 27 cases of prostate cancer, positive 25 cases, 2 cases of misdiagnosis, the coincidence rate is 92.6%, group C in 27 cases of prostate cancer, 26 patients, positive, 1 case of misdiagnosis, the coincidence rate was 96.3%. Three groups of patients were compared with difference had statistical ***: Combination of P504s (AMACR), basal cell specific markers (about and CK34 beta E12 at 11:45) detection diag
维普期刊数据库